ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

MLA

Flynn, Michael J., et al. “ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.” Molecular Cancer Therapeutics, vol. 15, no. 11, Nov. 2016, pp. 2709–21. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-16-0233.

APA

Flynn, M. J., Zammarchi, F., Tyrer, P. C., Akarca, A. U., Janghra, N., Britten, C. E., Havenith, C. E. G., Levy, J.-N., Tiberghien, A., Masterson, L. A., Barry, C., D’Hooge, F., Marafioti, T., Parren, P. W. H. I., Williams, D. G., Howard, P. W., van Berkel, P. H., & Hartley, J. A. (2016). ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Molecular Cancer Therapeutics, 15(11), 2709–2721. https://doi.org/10.1158/1535-7163.MCT-16-0233

Chicago

Flynn, Michael J, Francesca Zammarchi, Peter C Tyrer, Ayse U Akarca, Narinder Janghra, Charles E Britten, Carin E G Havenith, et al. 2016. “ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.” Molecular Cancer Therapeutics 15 (11): 2709–21. doi:10.1158/1535-7163.MCT-16-0233.